Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 08h05 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
23 déc. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. ...
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
12 nov. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
11 nov. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov. 11, 2021...
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
10 nov. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Live video webcast presentation on Monday, November 15th at 8:30 am ET PHILADELPHIA, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
01 nov. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant...
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
12 oct. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
14 sept. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Inaugural appointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 (GLOBE NEWSWIRE)...
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10 août 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
26 avr. 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...